PRESS RELEASE May 10 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced its “Saniona’s Community Voices” video series , which will feature the voices of people living with rare diseases, their caregivers and the ir medical

PRESS RELEASE April 30 , 2021 During April , the registered number of shares and votes in Saniona AB ( publ ) (“Saniona”) has increased due to the exercising of warrants of series TO 3 . As of April 30, 2020, the registered number of shares and votes in Saniona amounts to 62,385,677 .

PRESS RELEASE April 29 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the English version of the Annual R eport for 20 20 is now available on the company’s website , www.saniona.com .

PRESS RELEASE April 2 6 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it will participate in multiple upcoming investor conferences as follows: Redeye Orphan Day Wednesday, April 28, 2021 at 6:15 a.m.

PRESS RELEASE April 23, 2021 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the annual shareholders’ meeting

PRESS RELEASE April 2 2 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the outcome in the exercise of warrants of series TO3, that was issued in connection with Saniona’s rights issue and directed issue in the first quarter of

PRESS RELEASE April 2 2 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) regarding its proposed chemistry, manufacturing and controls (CMC) plans for Tesomet.

PRESS RELEASE April 19, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it has entered into a partnership with the Foundation for Prader-Willi Research (FPWR) to increase awareness within FPWR’s community about Saniona’s Phase 2b

PRESS RELEASE April 14, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its research team will present preclinical data on SAN903 in a model of idiopathic pulmonary fibrosis at the American Society of Pharmacology and

PRESS RELEASE April 12, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that, since December 2020 when its shareholdings in Scandion Oncology fell below 5%, Saniona has sold its remaining shares of Scandion Oncology A/S (Nasdaq First